Pharma Focus Asia
KP - Choose our fully recyclable blister films

Janssen Pharmaceutical Discovered First-of-its-Kind ERLEADA® (apalutamide)

The Janssen Pharmaceutical Companies of Johnson & Johnson discovered first-of-its-kind ERLEADA® (apalutamide) for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).

The androgen receptor inhibitor ERLEADA® (apalutamide) is used to treat non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC).

ERLEADA® (apalutamide), is available for patients as the first-and-only next-generation androgen receptor inhibitor with once-daily tablet.  

With two strengths available, the healthcare professionals consists of the flexibility to prescribe 240mg once-daily dose of ERLEADA® either in the form of one 240mg tablet or four 60mg tablets. The patients can prefer single-tablet option to reduce their total number of daily pills.

For patients having difficulty in swallowing tablets, ERLEADA® remains as the only single-tablet androgen receptor inhibitor (ARI) with alternate methods of administration. The 60 mg tablets are approved  for dispersion in applesauce, while the 240 mg tablets are approved for  orange juice, water or applesauce. The 240 mg tablet can also be delivered through a feeding tube.

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Is your drug program on trackMasterControl - Manufacturing demoMasterControl - QMS demoBora Pharmaceuticals - Free WhitepaperThermo Fisher Scientific - Rapid Mycoplasma TestingThermoFisher Scientific - Save costs on your downstream process todayThermo Fisher Scientific - PeptonesMerck - Mobius® products5th Annual Pharma Manufacturing and Automation Convention 2023DUPHAT 202410TH ANNUAL GCC PHARMACY CONGRESS 2023Reuters Events - Pharma Customer Engagement USA 202314th Annual Emirates Cardiac Society Conference 2023The International Hand & Wrist Congress 2023LabAsia 2023Pharma & Patient USA 2023Pharma Customer Engagement Europe 2023
MasterControl - 6 Essential Features in an eQMS